FIB-4 Index - Calculation, Interpretation, and What to Do When It’s Indeterminate
FIB-4 has become one of the most practical liver risk tools in primary care because it uses routine data and scales easily. Its weakness is also the reason elastography demand is growing: a large group of patients still lands in the indeterminate middle.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes. This content does not replace clinician judgement or individual medical advice.
Why FIB-4 matters
FIB-4 is a simple blood-based fibrosis risk score built from routine clinical variables. It has become central to modern screening because it is inexpensive, scalable, and easy to calculate in primary care.
In the Australian setting, it is particularly useful for GPs managing obesity, diabetes, and metabolic risk where broad screening is needed before deciding who requires second-line testing.
The indeterminate zone is the real problem
A major proportion of patients do not fall neatly into low- or high-risk categories. The playbook uses the figure of about 30% of results landing in the indeterminate zone, which is exactly where elastography becomes clinically valuable.
This is the part of the workflow where clinics either create access to second-line testing or lose time through fragmented referral pathways.
- Low-risk scores support reassurance and periodic follow-up.
- High-risk scores support escalation and specialist involvement.
- Indeterminate scores create the strongest case for elastography.
Limitations clinicians need to remember
FIB-4 is affected by age, platelet count, inflammation, and the fact that it is an indirect marker rather than a direct assessment of liver tissue. It is a triage tool, not a final answer.
That limitation is also why a high-quality second-line test with good access matters so much in general practice and metabolic care settings.
How FIB-4 and elastography work together
The most practical model is sequential: blood-based risk assessment first, elastography second when risk remains uncertain. This approach preserves access and cost-efficiency while improving specificity for advanced fibrosis.
For buyers, that means the device case is strongest in clinics already managing high-risk metabolic cohorts rather than trying to create demand from scratch.